The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
CREDIT DESIGNATION STATEMENT
The AACR has designated this live activity for a maximum of 14.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CLAIMING (CME) CREDIT
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this continuing medical education activity must complete the CME Request for Credit Survey below. Certificates will only be issued to those who complete the survey. CME certificates will be sent by email after the completion of the activity.
STATEMENT OF EDUCATIONAL NEED, TARGET AUDIENCE AND LEARNING OBJECTIVES
The latest advances in genetics, cell biology and molecular biology that are relevant to mammary development, transformation and breast cancer progress will bridge the gap and increase physicians’ knowledge in areas of stem cell biology, genetics and breast cancer risk, mouse models for breast cancer, genomic and proteomic approaches to tumor profiling, metastasis and breast cancer progression, oncogene signaling, the influence of tumor microenvironment on breast carcinogenesis, as well as state-of the-art imaging methods and the latest in molecular therapeutics for breast cancer. This exposure is essential for the implementation of best practices, such as the most current molecular-based tests to aid in the diagnosis, treatment and prevention of cancer. Further, facilitating the interface between physicians and scientists will increase knowledge of the epidemiological implications of cancer incidence and the contributions of laboratory research to drug development as well as patient care; transform the design and conduct of clinical research protocols; and create a forum for the rapid translation of laboratory research findings from “bench-to-bedside” for the benefit of improving patient outcomes.
After participating in this CME activity, physicians should be able to:
- Diagnose molecular and cellular mechanisms underlying inter- and intratumor heterogeneity in breast cancer and their clinical relevance especially as they relate to tumor progression and therapeutic resistance.
- Identify recent advances in comprehensive molecular profiling of breast tumors (e.g., genomic, epigenomic and metabolomic studies) aimed at the identification of new molecular biomarkers and therapeutic targets.
- Intepret the role of noncoding RNAs (e.g., microRNAs and long-noncoding RNAs), which comprise the majority of the mammalian transcriptome in breast cancer.
- Review the role of inflammation and changes in the local and systemic (e.g., whole body) microenvironment in breast cancer progression and therapeutic responses.
- Evaluate recent advances in targeted therapeutics and mechanisms underlying therapeutic resistance in breast cancer.
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.
ACKNOWLEDEMENT OF FINANCIAL OR OTHER SUPPORT
This activity is supported by grants and will be disclosed at the activity.
QUESTIONS ABOUT CME?
Please contact the Office of CME at (215) 440-9300 or email@example.com.